Tracon Termination of ENVASARC Trial and Will Explore Strategic Alternatives

 The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint of 11%

Company will focus on exploring strategic alternatives, that may include a variety of strategic transactions such as a reverse merger, acquisition, sale of all assets, or other strategic transactions leveraging its in-house Product Development Platform of CRO-independent clinical trial execution

https://www.biospace.com/article/releases/tracon-pharmaceuticals-announces-termination-of-envasarc-trial-and-will-explore-strategic-alternatives-leveraging-its-in-house-product-development-platform/